In the name of god.

Slides:



Advertisements
Similar presentations
Morphology substudy ELN low risk Registry Aims - assess the reproducibility of diagnosis Methods - review of random selected slides from all participating.
Advertisements

Coding Haematological Malignancies in Cancer Registries part I : Myeloid malignancies Pr Marc Maynadié Registre des Hémopathies Malignes de Côte d'Or Faculté.
Myelodysplastic and Myelodysplastic/ Myeloproliferative Neoplasms
Spliceosome mutations in myeloid neoplasms
NEOPLASTIC DISORDERS OF THE BONE MARROW
Myelodysplastic syndromes Achievements in understanding and treatment prof. dr hab. med. Krzysztof Lewandowski.
Myelodysplastic Syndromes
Myelodysplastic Syndrome
LEUKEMIA—HEMATOLOGY {S1}
Thrombocytopenia or thrombocytosis? Nancy Rosenthal, MD.
Myelodysplastic Syndrome
Week 12: Myelodysplastic Syndrome
Myelodysplastic syndrome and acute myeloid leukaemia
Myelodysplastic Syndromes Austin Kulasekararaj. Background and Why? Described in 1900 Defined as MDS only in 1982-abnormal clone (don’t think it spreads.
Lecture 6 and 7 Myelodysplastic syndromes; Chronic lymphocytic leukemia and related lymphoproliferative disorders Abdulkarim Aldosari.
HEMATOLOGIC MALIGNANCIES Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic.
Myelodysplastic Syndromes: Clonal Myeloid Diseases
Acute Myeloid Leukemias (AML)
Myelodysplastic syndrome overview Razelle Kurzrock Seminars in Haematology, Vol 39, No 3, Suppl 2 (July) 2002, pp
Myelodysplastic syndromes
Myelodysplastic Syndrome
Seyyed Reza Safaee MD Internist- Hematologist&Oncologist Hematology&Oncology& Hematopoietic Stem Cell Transplantation Ward Imam Khomeini General Hospital.
MPD. Myeloproliferative neoplasms (MPN) constitute one of five categories of myeloid malignancies, according to the World Health Organization (WHO) classification.
Conflicts of interest: none to declare Monika Klimkowska MD PhD Department of Pathology and Cytology Karolinska University Hospital Stockholm, Sweden.
Myelodysplastic Syndromes: An Update. 80 yo male: OSA, gout, CAD, and prostate cancer who was referred for progressive anemia. Past few months: noticed.
Myelodysplastic Syndrome (MDS)
The myelodysplastic syndromes (MDS) Aquired Clonal disease of BM. comprise a heterogeneous group of malignant stem cell disorders characterized by : 1.
MLAB HEMATOLOGY KERI BROPHY-MARTINEZ Myelodysplastic Syndromes.
بسم الله الرحمن الرحيم. Leukocytes Leukopenia Leukocytosis.
Morphology Review - ISH Slides - 제 2 차 혈액학 종합학술대회 발표 2000 년 5 월 25 일 -5 월 26 일 COEX 한림의대 조 현 찬.
Overview of Myelodysplastic Syndromes with Focus on Iron Overload Norbert Gattermann, MD, PhD Professor Department of Haematology, Oncology, and Clinical.
CB-1 MDS Classification and Prognosis John M. Bennett, MD University of Rochester Medical Center Hematomorphologist Chair, MDS Foundation.
1 MYELOPROLIFERATIVE SYNDROMES & LEUKEMIA Doç. Dr. Işın Doğan Ekici.
Myelodysplastic Syndromes Tefferi A, Vardiman JW. New Engl J Med 2009:361(19):
Myelodysplastic disorders
Heterogeneous group of hematopoietic neoplasms Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation Composed.
MLAB 1415: Hematology Keri Brophy-Martinez
Malignant diseases of the bone marrow Tornóci László Semmelweis University Institute of Pathophysiology.
MLAB Hematology Keri Brophy-Martinez
Acute Leukemia Kristine Krafts, M.D..
골수증식 질환 Myeloproliferative disorders (MPD) [ 새로운 분류와 진단 기준 ] 경희의대 종양혈액내과 조 경 삼.
CP Case Conference Aplastic Anemia 1/27/12 Laura Walters.
Anemia of Chronic Disease
Associate professor of Internal Medicine
MYELODYSPLASTIC SYNDROMES
Acute Leukemia Kristine Krafts, M.D..
Clinical and Histologic Evaluation of Myelodysplastic Syndromes
Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes  J. Loeffler-Ragg, U. Germing, W.R. Sperr, H. Herrmann, H. Zwierzina,
Acute Myeloid Leukemia
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Diagnosis and classification of myelodysplastic ring sideroblasts
MLAB Hematology Keri Brophy-Martinez
Algorithm for the classification of adult-onset primary myelodysplastic syndromes (MDS). This classification system is based on the 2008 criteria of the.
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Chronic leukemias CML CLL MDS.
HS 4160 Critical Scientific Analysis
Biology of MDS/MPN overlap syndromes (except CMML)
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice
The genetic basis of myelodysplasia and its clinical relevance
by Bartlomiej Przychodzen, Andres Jerez, Kathryn Guinta, Mikkael A
by R. Coleman Lindsley, and Benjamin L. Ebert
Erythroid maturation.
Myelodysplastic syndromes
Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes by Abdullah Mahmood Ali, Yumin Huang,
Lyons RM et al. J Clin Oncol 2009;27(11):
Hematology Journal Club
Chronic Leukemia Dr. Noha Noufal.
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
MYELOID LEUKEMIAS Dr. B.V.Vydehi M.D PROFESSOR OF PATHOLOGY
Presentation transcript:

In the name of god

Hematology Journal Club Classification of myelodysplastic syndrome Title: Classification of myelodysplastic syndrome Presented by: Fatemeh Jamshidi

Myelodysplastic syndrome (MDS)

definition Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by dysplastic, ineffective and neoplastic hematopoiesis. Transformation to AML is frequent.

characteristics 1 2 3 4 PB: Cytopenia BM: Hypercellular Dysplasia varying degree of tri-lineage cytopenia

incidence 70 years

clinical manifestations Anemia Infection bleeding

morphology Dyserythropoiesis Dysgranulopoiesis Dysmegakaryopoiesis

MDS classification history 2016 2008 WHO 1982 WHO FAB

FAB classification FAB subgroup PB blasts (%) BM Ring Sideroblasts (%) Monocytes (×10/L) RA < 1<1 ≤ 1 < 5 < 15 < 1 RARS ≤ 1 ≥ 15 RAEB 1 - 5 5 - 20 variable CMML < 20 > 1 RAEB-t ≥ 5 Auer rods 21 – 30

FAB Blasts (%) 20 – 30 ? Monocytes > 1000/ml ? RAEB-t Blasts (%) YES Monocytes > 1000/ml ? RAEB-t NO YES Blasts (%) 5 – 20 ? CMML NO YES RS (%) > 15 ? RAEB NO YES RA RARS

FAB WHO

FAB WHO × × RAEB-t CMML RAEB RA AML MDS/MPN RAEB-1 RAEB-2 RA RA RCUD RN RA RCMD RT

2008 WHO classification RCUD < 1 < 5 < 15 RARS _ ≥ 15 RCMD subgroup PB blasts (%) BM Ring Sideroblasts (%) Monocytes (×10³/L) RCUD < 1 < 5 < 15 RARS _ ≥ 15 RCMD RCMD-RS RAEB-1 5-9 RAEB-2 5-19 10-19 Auer rods Del (5q-) MDS-U

Del 5q- MDS(5q-) ? Auer rods RAEB-2 ? Blasts (%) RAEB-2 10 – 19 ? YES MDS(5q-) NO Auer rods ? YES RAEB-2 NO Blasts (%) 10 – 19 ? YES RAEB-2 NO Blasts (%) 5 – 9 ? YES RAEB - 1 YES RCMD-RS YES Multilineages ? NO RARS NO RS (%) > 15 ? YES RCMD Multilineages ? NO RA NO

2008 2016 WHO

2016 WHO classification WHO subgroup Dysplastic lineages cytopenias PB blasts (%) BM Ring sideroblasts (%) MDS-SLD 1 1 or 2 < 1 < 5 < 15 MDS-MLD 2 or 3 1 - 3 MDS-RS-SLD ≥ 15 MDS-RS-MLD MDS-del 5q 1 - 2 - MDS-EB-1 0 - 3 2 - 4 5 - 9 MDS-EB-2 5 – 19 Auer rods - 19 MDS-U RCC < 2

mutations

Ring sideroblasts

SF3B1??

Maturity of mRNA

snRNPs (snurps)

U2 snRNP

mutated sf3b1

mutated sf3b1 ABCB7 Ring Sideroblasts

THANK YOU AND LETS TALK